Ruti Aga's Six-Year Ban: A Knee Injection, a Forged Prescription, and the Arithmetic That Ran from Two Years to Six

The Athletics Integrity Unit's statement landed on a Thursday afternoon, and the first thing I saw in it was not a name. It was three numbers. One — a half marathon in China in March, where the sample was collected. Two — 10 September, from which Ruti Aga's provisional suspension had been running. Three — two years plus four years, equals six. A six-year ban, backdated to 10 September, which is to say a banishment that began when she was thirty-two and will not end until she is around thirty-eight, putting her outside the entire next Olympic cycle.

What is quoted in the fifth and sixth paragraphs of the statement is the anchor of this whole case. Everything else — the result of that March race, the quality of the field, the time, the splits — is nowhere on the record. And the rule I set four decades ago still holds: before the verdict, I lay the season. A season that is not on paper does not get a sentence from me.

Ruti Aga's record is clean in the documents. She won the Tokyo Marathon in 2026 — a World Marathon Majors title, and in this sport that is the category in which appearance fees, television and sponsorship are decided together. A year earlier she finished second in Berlin. Across the Majors she has three second-place finishes. For a runner in the 2:18 to 2:20 band, that is what I call 'title contention without title conversion' — she is on the sheet in every race, but her global championship medal count is zero.

What is said about the depth of Ethiopian women's marathon running is not exaggeration. A 2:18 runner does not walk into a national team there. So when I read the first draft of this news, it did not take long to see that the damage here has not landed on Ethiopia's medal budget. It has landed on one person's career. And the real question is what did the most damage to it — the substance or the paper.

The March race was in China. I have kept these Label road races in a separate ledger for years, because their economics are transparent: a large appearance fee, a deep East African elite field, and a reliable income tier in the gap between Majors. She won that race in March. That tells us only this much about her form — that she was running. Nothing more, because the time, the splits and the field quality are all absent from the statement. From a number that is not on the record, I do not derive form. That has been my rule for a long time, and it hardened after 2026, when I built a single-page start list before every meet I covered — the printed start list was the first document I trusted, and every name on it carried a season's best ahead of it.

Now the point that has been printed wrong almost everywhere. To call methylprednisolone a 'prohibited steroid' and to write that WADA classifies it as performance-enhancing is incomplete and misleading. Methylprednisolone is a glucocorticoid. On the WADA Prohibited List its class is S9. Anabolic steroids sit in S1. That difference is not clerical; it is the spine of this case. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection given out-of-competition is entirely lawful. It becomes a violation only if residues are present in a sample taken in-competition. On the road, the testing window opens at 23:59 the day before the race, so an injection given days earlier can still be caught.

The consequence is plain: the centre of this case was never what she took, but when and by which route. That was the legal ground on which a defence could have stood. An athlete who could give a clean account of timing, route and medical necessity could have argued the presence charge down to 'no fault' or 'no significant fault'.

According to the statement, she cited a knee injury. Knee injury is so common among marathoners that it is credible on its face — intra-articular or peri-articular methylprednisolone is standard sports-medicine practice in distance running. Precisely for that reason, a defence built on real records would have been strong. But the records were not real.

The prescription was written by a family member — a person with no medical registration, who claimed to have used 'an old prescription pad from a former workplace'. The clinic cited did not exist; and that clinic stated plainly that it had no connection to the pad. Three separate verification points, three separate failures. This is not a filing error. It is the fingerprint of a system in which an elite athlete is operating without a credentialed team physician.

Now the arithmetic I have been holding back an entire paragraph for. Two years for the presence violation. Four years for tampering — that is, the forged prescription and the misleading statement made in interview. Six in total. The arithmetic is itself a document. The WADA Code structure allows the presence sanction to be reduced if a panel accepts no fault or no significant fault. Staying at two years means the panel rejected that mitigation. And four years is the standard tampering sanction, meaning that limb was treated as fully culpable. There is an interesting tension here: forged documentation is, in itself, circumstantial evidence of concealment intent, yet it did not escalate the presence sanction. The panel kept the two in separate accounts — the substance in one, the document in another. The outcome is that of the six years, four were served not for the substance but for the paper.

The scope of disqualification is not stated. The statement does not say whether the March result and its prize money were annulled. Standard AIU practice is automatic disqualification of the competition at which the sample was collected, along with the forfeiture of ranking points accrued after that date. But standard practice and a recorded decision are two different things. I will wait for the second and, until then, file this as unconfirmed.

And here is the part least written about: the 2026 Tokyo title. The violation is anchored to a race in March of a later year. Unless there is a finding of earlier use, results before that date are not automatically annulled. On paper, she is still the 2026 Tokyo Marathon winner. That is the most uncomfortable truth in this file — she was a genuine elite marathoner, and she is now a name sponsors will keep their distance from. The tape is a witness, and I prefer witnesses to experts; in this case the tape is that 2026 race, which no file can erase.

The optics say: a cheat was caught, six years were handed down, fair enough. The ledger says something else.

First, the choice of substance. Methylprednisolone has no proven endurance benefit. It reduces swelling and suppresses pain. It is the substance a damaged runner uses to be pulled through to the next race, not one used to win the race a year later. And a six-year ban for this substance has arrived at a time when four years is common in anabolic steroid cases. I am not saying the sanction is wrong — the four tampering years are written into the Code, and having a forged prescription manufactured is a deliberate act. But I will say this much: when the largest share of a sanction comes not from the substance but from the paperwork, selling it under the headline of 'tough action on doping' is a dishonest translation.

Second — and this is what troubles me most — whose conduct are we auditing? The statement contains a family member, an athlete, and a clinic that does not exist. It does not contain an agent, a manager, a training camp, a team physician. But a thirty-two-year-old runner from the deepest marathon system in the world does not suddenly decide on her own where to get a knee injection and who will write the slip. Someone advised. Someone accepted the document. Someone looked past the process. The statement is silent on those names.

Third — and this is what I call routing the critique upward. Had this athlete had a credentialed team physician, there would have been a real prescription. Had there been a real prescription, there would have been a TUE or a route-and-timing note. Had there been such a note, the presence charge would have moved toward 'no significant fault', and the four-year tampering account would never have opened at all. This case, which is now career-ending, might have ended as a warning. The real failure, then, was not the substance. The real failure was that no medical governance existed around an elite marathoner at all.

Fourth — the economics of China's Label races. For East African marathoners these races fill the income gap between Majors: large appearance fees, low risk, few races. They are now also the AIU's most productive testing ground. The appearance-fee market and the testing market are colliding on the same track. An empty stadium audits every assumption the crowd used to hide — and here the crowd was present, but surveillance made it irrelevant. This collision will produce more cases, because the same system that sent one athlete onto a start line without a physician will send the next one too.

Three things to watch. One: the CAS appeal window — typically around twenty-one days from the reasoned decision — and whether an appeal is actually filed. Document-based findings are hard to overturn, so the probability is low, but the window is open. Two: the scope. When the March result and prize money are formally annulled, and whether any later race is affected. Three: the silence. No statement has come from the Ethiopian federation, and that silence carries its own weight.

One thing is settled. When the largest share of a six-year ban is handed down not for a substance but for paper, the sport is sending a message that its biggest enemy is not the body but the file. Next season, when an Ethiopian runner stands on a start line with a sore knee, her first question will not be where to get the injection. Her first question will be who signed a document she may one day have to prove. That is this ruling's real inheritance — and it is one no medal table will ever show.